<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107686">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02045563</url>
  </required_header>
  <id_info>
    <org_study_id>PETIT PARI 2011</org_study_id>
    <nct_id>NCT02045563</nct_id>
  </id_info>
  <brief_title>Genetic Polymorphisms, Steatosis and Diabetes</brief_title>
  <official_title>Genetic Polymorphisms, Hepatic Steatosis and Lipid Anomalies in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Our research hypothesis is to show that a certain number of genetic polymorphisms of
           the proteins involved in glucose, lipid and adipocyte metabolism are factors that
           favour the development of steatosis in patients with Type 2 diabetes.

        -  We also wish to evaluate more thoroughly lipid anomalies associated with the presence
           of steatosis, notably with regard to monocyte expression of LDL receptors. We
           hypothesize that hepatic steatosis is accompanied by activation of transcription
           factors involved in lipogenesis, notably SREBP factors. The activation of these factors
           could cause an increase in the expression of LDL receptors, leading to increased LDL
           catabolism.

        -  Chronological description of the study During an outpatient consultation at the
           endocrinology department, diabetic patients, programmed to undergo an examination to
           assess their diabetes will be invited to participate in the study. Once written
           informed consent has been provided and clinical data has been recorded, patients with
           type 1 or type 2 diabetes will have standard biological examination, which is
           systematically done in such patients (Fasting glycemia, HBA1c, aspartate
           aminotransferase, alanine amino transferase, Gammaglutamyl-transferases, PAL,
           bilirubin, blood proteins, albuminemia, Total Cholesterol total, HDL cholesterol,
           triglycerides, Sedimentation Rate, C-reactive protein, fibrinogen).

      As well as the systematic biological tests, 3 additional tubes will be taken to screen for
      genetic polymorphism in 3 proteins (Microsomal Transfer Protein, Adiponectin receptor - 1,
      Apolipoprotein A - II).

      IN addition, magnetic resonance imaging and magnetic resonance spectroscopy will be done to
      look for the presence of liver steatosis and to measure carotid intima-media thickness.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Determination of the existence of liver steatosis measured by magnetic resonance spectroscopy  spectrometry</measure>
    <time_frame>At inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of monocyte expression of LDL receptors</measure>
    <time_frame>At inclusion</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">587</enrollment>
  <condition>Type 1 and 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Patients with type-1 diabetes</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with type-2 diabetes</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Volontaires sains</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>prise de sang</intervention_name>
    <arm_group_label>Patients with type-1 diabetes</arm_group_label>
    <arm_group_label>Patients with type-2 diabetes</arm_group_label>
    <arm_group_label>Volontaires sains</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>magnetic resonance imaging and magnetic resonance spectroscopy</intervention_name>
    <arm_group_label>Patients with type-1 diabetes</arm_group_label>
    <arm_group_label>Patients with type-2 diabetes</arm_group_label>
    <arm_group_label>Volontaires sains</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of type 2 diabetes over 18 subjects treated with diet alone
        or with oral antidiabetic glitazones outside of patients with type 1 and of age-matched
        healthy volunteers and sex.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria Type-2 diabetics:

          -  Type 2 diabetes

          -  HbA1C&gt;6.5%

          -  27&lt;BMI&lt;55

        Inclusion criteria Type-1 diabetics:

          -  Type 1 diabetes

          -  BMI&lt;55 Diagnosis of type-1 diabetes based on the clinical history of the patient
             and/or the presence of anti-glutamate decarboxylase auto antibodies and/or a plasma
             level of C peptide below 0,5 ng/l.

        Inclusion criteria healthy volunteers:

          -  Non diabetic

          -  Alcohol consumption &lt; 2 glasses per day

          -  Without hyperglycemic treatment (corticoids, ...)

          -  Without liver disease (cirrhosis, hepatitis, ...)

        Exclusion Criteria:

          -  Pacemaker

          -  Daily alcohol consumption above 4 glasses per day

          -  Patients treated with Glitazones during the 3 months preceding inclusion

          -  Presence of implants

          -  Claustrophobia

          -  Patient &lt; 18 years

          -  Patient under guardianship or not intellectually independent

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Michel PETIT</last_name>
    <phone>3 80 29 34 53</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-michel.petit@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michel PETIT</last_name>
      <phone>3 80 29 34 53</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-michel.petit@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>January 23, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
